The recommendations for systemic therapy in metastatic renal cancer have recently been undergoing dramatic changes in Japan, and the recommended first‐line therapy for ccRCC has become IO combination therapy or IO plus VEGFR‐TKI therapy. The gene discussed is KDR; the disease is nonpapillary renal cell carcinoma.